ClinicalTrials.gg
RecruitingNCT06828887Updated Oct 20, 2026

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD

A Phase 2 interventional study of LV232 40mg and LV232 60mg in MDD, sponsored by Vigonvita Life Sciences. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Vigonvita Life Sciences · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Oct 20, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding Phase II clinical trial aimed to determine the optimal dose of LV232 capsules for treating MDD, evaluate preliminary efficacy and safety, and provide a basis for Phase III trial design and dosing regimen determination.

Read the detailed description

This study adopts a multicenter, randomized, double-blind, placebo- and active-controlled parallel-group clinical trial design, aiming to evaluate the efficacy and safety of LV232 capsules ( 40 mg, and 60 mg, once daily) in patients with major depressive disorder (MDD).

The trial plans to enroll 400 subjects, stratified by first episode or recurrence of the disease. Participants will be randomized in a 1:1:1:1 ratio into five groups: LV232 capsules 40 mg, 60 mg, placebo, and active control, with 100 subjects in each group. The treatment will be administered once daily for 8 consecutive weeks.

02

Conditions studied

  • MDD
03

In context

Lead sponsor

Vigonvita Life Sciences is the lead sponsor of 39 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully understand the purpose, content, and potential adverse reactions of this trial, voluntarily participate in the clinical trial and sign a written form, able to complete the entire trial process as required and comply with the trial regulations;
  2. Gender unrestricted, at screening: 18 years old ≤ age ≤ 65 years old;
  3. Meet the (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) diagnostic criteria for depression according to the Mini International Neuropsychiatric Interview (M.I.N.I. 7.0.2), currently experiencing a single or multiple episodes;
  4. For first-episode patients, the duration of the current depressive episode must be ≥3 months; for recurrent patients, the duration of the current depressive episode must be ≥1 month (each month is counted as 30 days, the same applies below);
  5. During the screening and baseline periods, the total score on the Montgomery-Asberg Depression Rating Scale (MADRS) must be ≥26, and the Clinical Global Impression-Severity (CGI-S) score must be ≥4;
  6. At screening and baseline visits, the score on the first item (depressed mood) of the HAMD-17 scale must be ≥2;
  7. Female or male subjects of agree and commit to using effective from the signing of the informed consent form until 3 months after the last administration of the trial drug.

Exclusion criteria

Exclusion Criteria:

  1. Treatment-resistant depression (failure to respond to an adequate dose and duration of treatment, at least 8 weeks, with two antidepressants of different mechanisms) or failure to respond to an adequate dose and duration of treatment with escitalopram oxalate;
  2. Meeting the diagnostic criteria for other mental disorders as per (such as schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, generalized anxiety disorder, obsessive-compulsive and related disorders, somatic symptom and related disorders, etc.);
  3. Meeting the DSM-5 criteria for substance use disorder;
  4. Organic mental disorders, such as depression caused by hypothyroidism;
  5. Depression induced by psychoactive substances or non-addictive substances;
  6. Presence of depressive symptoms due to other diseases or other types of mental disorders;
  7. A reduction of ≥25% in the MADRS score at baseline compared to the screening period;
  8. Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) and judged by the investigator to be at risk of suicide, or having suicidal behavior within the 6 months prior to screening;
  9. Presence of severe physical illnesses deemed by the investigator as grounds for exclusion, such as uncontrolled hypertension or severe unstable cardiovascular diseases, severe liver diseases, kidney diseases, blood diseases, endocrine diseases, neurological diseases, etc.;
  10. Diseases affecting oral drug absorption, such as active bowel disease, partial or complete intestinal obstruction, chronic diarrhea, etc.;
  11. Active or a history of malignancy within 5 years prior to screening (except for completely resected and cured squamous cell carcinoma, cervical carcinoma in situ, etc.);
  12. History of increased intraocular pressure or narrow-angle glaucoma;
  13. Individuals with allergic constitution, such as those allergic to two or more drugs or known to be allergic to escitalopram oxalate;
  14. Use of drugs that alter the activity of liver enzymes (CYP2C19 and CYP2D6) within 4 weeks (or 5 half-lives, whichever is longer) prior to randomization (see Appendix 2);
  15. Previous treatment with vagus nerve stimulation (VNS) and deep brain stimulation (DBS), or modified electroconvulsive therapy (MECT) within 3 months prior to randomization, or systematic psychotherapy (interpersonal therapy, dynamic therapy, cognitive behavioral therapy), transcranial magnetic stimulation (TMS), and light therapy within 1 month prior to randomization, or judged by the investigator to currently require such treatments;
  16. Systematic antidepressant treatment within 2 weeks prior to randomization (not less than 30 days for fluoxetine), or discontinuation of psychotropic drugs for less than 5 half-lives prior to randomization (except for stable doses of sleep aids received within 4 weeks prior to randomization, including benzodiazepines (limited to estazolam, alprazolam, and oxazepam) and non-benzodiazepines);
  17. Use of monoamine oxidase inhibitors such as phenelzine, isocarboxazid, tranylcypromine, etc., and linezolid, methylene blue, etc., within 2 weeks prior to randomization;
  18. Second or third-degree atrioventricular block, long syndrome, or QTcF > 450 ms (male)/460 ms (female) on 12-lead at screening;
  19. Discontinuation of drugs that prolong the QT interval (such as levofloxacin, fluconazole, ondansetron, amiodarone, metronidazole, erythromycin, and haloperidol, etc.) or drugs that may cause QT interval prolongation and induce torsade de pointes (TdP) for less than 5 half-lives at randomization;
  20. or AST above 2 times the ; creatinine above 1.5 times the upper limit of normal; 2 or more abnormal indicators in thyroid function tests (TSH, FT3, FT4, TT3, or TT4 below 0.9 times the lower limit of normal or above 1.1 times the upper limit of normal) at screening;
  21. Positive for Treponema pallidum antibody and antibody at screening;
  22. Substance abuse (including alcohol, drugs, and other psychoactive substances) within 3 months prior to screening;
  23. Female subjects who are breastfeeding or have a positive pregnancy test at screening or during the trial;
  24. Participation in any interventional clinical trial and use of drugs or medical devices within 3 months prior to screening, or currently participating in other clinical trials;
  25. Other factors deemed by the investigator as unsuitable for participation in the trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    LV232 capsules

    Capsule, 40 mg or 60 mg, administered orally once daily for 8 consecutive weeks

    Drug: LV232 40mg · Drug: LV232 60mg

  • Active comparator
    Escitalopram

    Tablet, 10 mg , administered orally once daily for 8 consecutive weeks

    Drug: Escitalopram

  • Placebo comparator
    Placebo

    Capsule/Tablet, administered orally once daily for 8 consecutive weeks

    Drug: Placebo

Interventions

  • LV232 capsules 2 capsules (20 mg/capsule) + LV232 capsule placebo 1 capsule + escitalopram oxalate tablet placebo 1 tablet

    Also known as: Low-dose group

  • LV232 capsules 3 capsules (20 mg/capsule) + escitalopram oxalate tablet placebo 1 tablet

    Also known as: High-dose group

  • LV232 capsule placebo 3 capsule + escitalopram oxalate tablet 1 tablet

    Also known as: Active Comparator

  • DrugPlacebo

    LV232 capsule placebo 3 capsule + escitalopram oxalate tablet placebo 1 tablet

    Also known as: Placebo Comparator,

06

What researchers measure

Primary outcomes

  1. Change from baseline in Montgomery Asperger Depression Scale (MADRS) score at the end of treatment (week 8)

    The MADRS is a clinician-rated scale used to evaluate depressive symptoms over the preceding week. Participants are assessed on 10 items-including feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest-each scored on a 7-point scale (0 = no symptoms, 6 = maximum severity). The total score ranges from 0 to 60, with higher scores indicating greater depression severity. A negative change in score signifies improvement. Change = (Week 8 post-dose score - baseline week 0 score). at the end of treatment (week 8)

    Time frame: Baseline and week 8

Secondary outcomes

  1. Change from baseline in Hamilton Depression Scale (HAMD-17) at week 8

    The HAMD-17 is a 17-item, clinician-rated scale that assesses depressive symptoms. The HAMD-17 consists of 17 symptoms, each of which is rated from 0 to 2 or 0 to 4, where 0 is none/absent. The HAMD-17 total score is calculated as the sum of the 17 individual symptom scores; the total score can range from 0 to 52. Higher HAMD-17 scores indicate more severe depression. Change = (Week 8 post-dose score - baseline week 0 score).

    Time frame: Baseline, week 8

  2. Change from baseline in Hamilton Anxiety Inventory (HAMA) scores at week 8

    The HAMA is used as a rating measure of anxiety severity. The scale consists of 14 items. Each item is rated on a scale of 0 to 4. The HAMA total score is the sum of the 14 items and the score ranges from 0 to 56, 0 is considered the best outcome. Change = (Week 8 post-dose score - baseline week 0 score).

    Time frame: Baseline, week 8

  3. Change from baseline in CGI-S score at week 8

    The CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment. The CGI-S will provide an overall clinician-determined summary measure that takes into account all available information including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. Change = (Week 8 post-dose score - baseline week 0 score).

    Time frame: Baseline and week 8

  4. CGI-I score at week 8

    The CGI-I assesses the subject's improvement (or worsening). The rater is required to assess the subject's condition relative to baseline\* on a 7-point scale. In all cases, the assessment should be made independent of whether the rater believes the improvement is study medication-related or not.

    Time frame: Baseline, week 8

  5. Change from baseline in PHQ-9 score at week 8

    The PHQ-9 scale consists of 9 items, each corresponding to a core symptom of depression, including depressed mood, loss of interest, sleep disturbances, fatigue, changes in appetite, feelings of guilt, difficulty concentrating, psychomotor retardation or agitation, and suicidal thoughts. Patients are required to rate each item based on their experiences over the past two weeks, with scores ranging from 0 (not at all) to 3 (nearly every day). The total score ranges from 0 to 27, with higher scores indicating more severe depressive symptoms.

    Time frame: Baseline, week 8

  6. Change from baseline in PDQ-D5 score at week 8

    The PDQ-D5 is used to assess cognitive symptoms, describing potential issues that participants may experience with memory, attention, or concentration. Based on their experiences over the past 7 days, participants select the most appropriate option for each item. The scale consists of 5 items, each with 5 response options (scored 0-4). The total score ranges from 0 to 20, with higher scores indicating more severe cognitive symptoms.

    Time frame: Baseline, week 8

  7. Change from baseline in DSST score at week 8

    The DSST (Digit Symbol Substitution Test) is used to assess processing speed, attention, and visuomotor coordination. Based on a digit-symbol coding key where each number 1-9 corresponds to a unique symbol, participants match as many symbols to their corresponding numbers as possible within 90 seconds. Higher scores indicate better cognitive function.

    Time frame: Baseline and week 8

  8. Change from baseline in SHAPPS score at week 8

    The SHAPS (Snaith-Hamilton Pleasure Scale) consists of 14 items assessing hedonic responses to common daily life situations, including but not limited to eating, hobbies/recreational activities, and other typical sources of pleasure.

    Time frame: Baseline and week 8

  9. SMQD score at week 8

    The Somatic Symptoms Questionnaire for Mental Disorders (SQMD) is a self-rated assessment tool primarily designed to evaluate the severity of common somatic symptoms associated with psychiatric disorders-including depressive disorders, bipolar disorders, anxiety disorders, and somatic symptom disorders-over the past week.

    Time frame: Baseline and week 8

  10. MARS score at week 8

    The Medication Satisfaction Rating Scale (MSRS) is a self-rated questionnaire designed to assess patients' satisfaction levels with their current medication regimen.

    Time frame: week 8

  11. Change from baseline in ASEX score at week 8

    The Arizona Sexual Experience Scale (ASEX) is a 5-item rating scale where each item is scored from 1 (hyperfunction) to 6 (hypofunction), with gender-specific versions (male and female) tailored to the assessed individual.

    Time frame: Baseline and week 8

  12. Change from baseline in C-SSRS score at week 8

    The Columbia Suicide Severity Rating Scale (C-SSRS) is a standardized clinical instrument specifically designed for the assessment of suicide risk.

    Time frame: Baseline and week 8

  13. Incidence of adverse events (AE)

    The AEs will be assessed according to the National Cancer Institute (NCI) CTCAE v5.0.

    Time frame: Throughout the study period

07

Study locations

1 of 1 sites recruiting
  • Shanghai Mental Health Center Ethics Committee
    Shanghai, China
    Recruiting
    • Shen yi feng · Contact021-34773308
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2025 (actual). Primary completion is estimated for Sep 2027, 28 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Sep 2026 → Sep 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Feb 17, 2025
StartActual
Apr 3, 2025
Primary completionEst.
Sep 1, 2027was Sep 2026
CompletionEst.
Dec 20, 2027was Dec 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 1, 2026→Sep 1, 2027
Oct 20, 2026
Study completion
Dec 20, 2026→Dec 20, 2027
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Primary completion Sep 1, 2026→Sep 1, 2027
    Study completion Dec 20, 2026→Dec 20, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06828887
Responsible party
Sponsor
First posted
Feb 17, 2025
Start date
Apr 3, 2025
Primary completion
Sep 1, 2027 (estimated)
Completion
Dec 20, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Duan Huaqing
Contact
huaqing.duan@vigonvita.cn
+86-18061926005
Li Huafang
principal investigator · Shanghai Mental Health Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LV232

Start the discussion